Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Eli Lilly & Co. has disclosed new calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1 (PDE1) inhibitors reported to be useful for the treatment of chronic kidney disease, ...